KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2897-2906

  Stewart, Michelle L ^a   Tamayo, Pablo ^a   Wilson, Andrew J ^b   Wang, Stephanie ^a   Chang, Yun Min ^a   Kim, Jong W ^a   Khabele, Dineo ^b   Shamji, Alykhan F ^a   Schreiber, Stuart L ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; DNA METHYLTRANSFERASE 1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NAVITOCLAX; PROTEIN BCL 2; RAS PROTEIN; VORINOSTAT; AZACITIDINE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MELANOMA CELL LINE; MOUSE; NONHUMAN; ONCOGENE K RAS; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MUTATION; NUDE MOUSE; ONCOGENE RAS; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANIMALS; AZACITIDINE; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942941263     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2860     Document Type: Article

References (35)

1. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129-39.
2. Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2010;2:71-86.
3. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
4. Kantarjian H1, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7.
5. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010;10:241-53.
6. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 2013;154:1151-61.
7. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
8. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
9. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 2013;9:643-50.
10. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011;7:566-74.
11. Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A 2012; 109: 15115-20.
12. Joe H. Relative Entropy Measures of Multivariate Dependence. J Am Stat Assoc 1989;84:157-64
13. Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, Botvinnik OB, et al. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal 2012;5:rs4.20.
14. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739-40.
15. Abe T, Toyota M, Suzuki H, Murai M, Akino K, Ueno M, et al. Upregulation of Bnip3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 2005;40: 504-10.
16. Ellinger-Ziegelbauer H, Kelly K, Sienbenlist U. Cell cycle arrest and reversion of Ras-induced transformation by conditionally activated form of mitogen-activated protein kinase kinase kinase 3. Mol Cell Biol 1999;19: 3857-68.
17. Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem 2000;275: 38973-80
18. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
19. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2012;490:609-15.
20. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007; 449:1073-7.
21. Wajapeyee N, Malonia SK, Palakurthy RK, Green MR. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev 2013;27:2221-6.
22. Lu R, Wang X, Chen ZF, Sun DF, Tian ZQ, Fang JY. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem 2007;282:12249-59.
23. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011;17:1582-90.
24. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008, 61:759-766.
25. Alcazar O, Achberger S, Aldrich W, Hu A, Negrotto S, Saunthararajah Y, et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer 2012;131:18-29.
26. Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013;32:1207-15.
27. An JH, Lee H, Paik SG. Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway. Mol Cells 2011;31:579-83.
28. An JH, Maeng O, Kang KH, Lee JO, Kim YS, Paik SG, et al. Activation of Ras up-regulateds pro-apoptoic BNIP3 in nitric oxide-induced cell death. J Biol Chem 2006;281:33939-48.
29. Kalas W, Swiderek E, Rapak A, Kopij M, Rak J, Strzadala L. H-ras up-regualates expression of BNIP3. Anticancer Res 2011;m31:2869-75.
30. Ng KP1, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, et al. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 2011;25:1739-50.
31. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-848.
32. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126.
33. Pakneshan P, Szyf M, Rabbani SA. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2005;26:557-664.
34. Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 2010;116:195-201.
35. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012;72: 2197-205.